Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):1954–1958. doi: 10.1128/aac.39.9.1954

Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.

E W van Etten 1, M T ten Kate 1, L E Stearne 1, I A Bakker-Woudenberg 1
PMCID: PMC162862  PMID: 8540697

Abstract

Pegylated amphotericin B (AmB) liposomes (PEG-AmB-LIP) were compared with laboratory-prepared nonpegylated AmB liposomes (AmB-LIP), a formulation with a lipid composition the same as that in AmBisome, as well as with industrially prepared AmBisome regarding their in vitro antifungal activities, toxicities, blood residence times, and therapeutic efficacies. Killing of Candida albicans (> 99.9%) during short-term (6-h) incubation was observed at 0.2 mg of AmB per liter for AmB desoxycholate, 0.4 mg of AmB per liter for PEG-AmB-LIP, 0.8 mg of AmB per liter for AmB-LIP, and 12.8 mg of AmB per liter for AmBisome. The maximum tolerated doses of PEG-AmB-LIP, AmB-LIP, and AmBisome were 15, 19, and > 31 mg of AmB per kg of body weight, respectively. In contrast to AmB-LIP, the blood residence time of PEG-AmB-LIP was prolonged and dose independent. In a model of systemic candidiasis in leukopenic mice at a dose of 5 mg of AmB per kg, PEG-AmB-LIP was completely effective and AmB-LIP was partially effective, whereas AmBisome was not effective. AmB-LIP at 11 mg of AmB per kg was partially effective. AmBisome at 29 mg of AmB per kg was completely effective. In conclusion, the therapeutic efficacies of AmB liposomes can be improved by preparing AmB liposomes in which a substantial reduction in toxicity is achieved while antifungal activity is retained. In addition, therapeutic efficacy is favored by a prolonged residence time of AmB liposomes in blood.

Full Text

The Full Text of this article is available as a PDF (205.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AMES B. N., DUBIN D. T. The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. J Biol Chem. 1960 Mar;235:769–775. [PubMed] [Google Scholar]
  2. Adler-Moore J. P., Chiang S. M., Satorius A., Guerra D., McAndrews B., McManus E. J., Proffitt R. T. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother. 1991 Oct;28 (Suppl B):63–71. doi: 10.1093/jac/28.suppl_b.63. [DOI] [PubMed] [Google Scholar]
  3. Allen T. M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991 Jul 1;1066(1):29–36. doi: 10.1016/0005-2736(91)90246-5. [DOI] [PubMed] [Google Scholar]
  4. Allen T. M., Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991 Sep 30;1068(2):133–141. doi: 10.1016/0005-2736(91)90201-i. [DOI] [PubMed] [Google Scholar]
  5. Anaissie E., Paetznick V., Proffitt R., Adler-Moore J., Bodey G. P. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis. 1991 Aug;10(8):665–668. doi: 10.1007/BF01975823. [DOI] [PubMed] [Google Scholar]
  6. Bakker-Woudenberg I. A., Lokerse A. F., ten Kate M. T., Mouton J. W., Woodle M. C., Storm G. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis. 1993 Jul;168(1):164–171. doi: 10.1093/infdis/168.1.164. [DOI] [PubMed] [Google Scholar]
  7. Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta. 1990 Nov 2;1029(1):91–97. doi: 10.1016/0005-2736(90)90440-y. [DOI] [PubMed] [Google Scholar]
  8. Clemons K. V., Stevens D. A. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrob Chemother. 1993 Sep;32(3):465–472. doi: 10.1093/jac/32.3.465. [DOI] [PubMed] [Google Scholar]
  9. Francis P., Lee J. W., Hoffman A., Peter J., Francesconi A., Bacher J., Shelhamer J., Pizzo P. A., Walsh T. J. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis. 1994 Feb;169(2):356–368. doi: 10.1093/infdis/169.2.356. [DOI] [PubMed] [Google Scholar]
  10. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  11. Gates C., Pinney R. J. Amphotericin B and its delivery by liposomal and lipid formulations. J Clin Pharm Ther. 1993 Jun;18(3):147–153. doi: 10.1111/j.1365-2710.1993.tb00605.x. [DOI] [PubMed] [Google Scholar]
  12. Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989 Sep;33(9):1544–1548. doi: 10.1128/aac.33.9.1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Heaton W. A., Davis H. H., Welch M. J., Mathias C. J., Joist J. H., Sherman L. A., Siegel B. A. Indium-III: a new radionuclide label for studying human platelet kinetics. Br J Haematol. 1979 Aug;42(4):613–622. doi: 10.1111/j.1365-2141.1979.tb01174.x. [DOI] [PubMed] [Google Scholar]
  14. Huang S. K., Lee K. D., Hong K., Friend D. S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992 Oct 1;52(19):5135–5143. [PubMed] [Google Scholar]
  15. Janknegt R., de Marie S., Bakker-Woudenberg I. A., Crommelin D. J. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet. 1992 Oct;23(4):279–291. doi: 10.2165/00003088-199223040-00004. [DOI] [PubMed] [Google Scholar]
  16. Klibanov A. L., Maruyama K., Torchilin V. P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990 Jul 30;268(1):235–237. doi: 10.1016/0014-5793(90)81016-h. [DOI] [PubMed] [Google Scholar]
  17. Lyman C. A., Walsh T. J. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs. 1992 Jul;44(1):9–35. doi: 10.2165/00003495-199244010-00002. [DOI] [PubMed] [Google Scholar]
  18. Pahls S., Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis. 1994 May;169(5):1057–1061. doi: 10.1093/infdis/169.5.1057. [DOI] [PubMed] [Google Scholar]
  19. Papahadjopoulos D., Allen T. M., Gabizon A., Mayhew E., Matthay K., Huang S. K., Lee K. D., Woodle M. C., Lasic D. D., Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460–11464. doi: 10.1073/pnas.88.24.11460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Proffitt R. T., Satorius A., Chiang S. M., Sullivan L., Adler-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):49–61. doi: 10.1093/jac/28.suppl_b.49. [DOI] [PubMed] [Google Scholar]
  21. Schmitt H. J. New methods of delivery of amphotericin B. Clin Infect Dis. 1993 Nov;17 (Suppl 2):S501–S506. doi: 10.1093/clinids/17.supplement_2.s501. [DOI] [PubMed] [Google Scholar]
  22. Woodle M. C. 67Gallium-labeled liposomes with prolonged circulation: preparation and potential as nuclear imaging agents. Nucl Med Biol. 1993 Feb;20(2):149–155. doi: 10.1016/0969-8051(93)90107-6. [DOI] [PubMed] [Google Scholar]
  23. Woodle M. C., Lasic D. D. Sterically stabilized liposomes. Biochim Biophys Acta. 1992 Aug 14;1113(2):171–199. doi: 10.1016/0304-4157(92)90038-c. [DOI] [PubMed] [Google Scholar]
  24. Woodle M. C., Matthay K. K., Newman M. S., Hidayat J. E., Collins L. R., Redemann C., Martin F. J., Papahadjopoulos D. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta. 1992 Apr 13;1105(2):193–200. doi: 10.1016/0005-2736(92)90194-q. [DOI] [PubMed] [Google Scholar]
  25. de Marie S., Janknegt R., Bakker-Woudenberg I. A. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother. 1994 May;33(5):907–916. doi: 10.1093/jac/33.5.907. [DOI] [PubMed] [Google Scholar]
  26. van Etten E. W., Otte-Lambillion M., van Vianen W., ten Kate M. T., Bakker-Woudenberg A. J. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother. 1995 Apr;35(4):509–519. doi: 10.1093/jac/35.4.509. [DOI] [PubMed] [Google Scholar]
  27. van Etten E. W., van den Heuvel-de Groot C., Bakker-Woudenberg I. A. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J Antimicrob Chemother. 1993 Nov;32(5):723–739. doi: 10.1093/jac/32.5.723. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES